Results from Phase 1 trial expected by end of 2014 or early 2015; BL-8040 also in midst of Phase 2 trial for AML, with results expected in early 2015 JERUSALEM-- --BioLineRx Ltd. , a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today dosing of the first ... (more)
http://ift.tt/1rpnXPs
http://ift.tt/1rpnXPs
No comments:
Post a Comment